NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML
This article was originally published in Scrip
Executive Summary
In its final guidance, the health technology appraisal institute for England and Wales, NICE, has stuck to an earlier recommendation that saw Bristol-Myers Squibb's Sprycel (dasatinib) lose out to Novartis' Tasigna (nilotinib) as an NHS funded treatment option for chronic and accelerated phases of chronic myeloid leukaemia (CML) that is resistant or intolerant to standard-dose imatinib (Novartis' Glivec).